MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Checkpoint Therapeutics Inc

Cerrado

SectorSanidad

4.03 -0.25

Resumen

Variación precio

24h

Actual

Mínimo

3.98

Máximo

4.04

Métricas clave

By Trading Economics

Empleados

23

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+31.19% upside

Dividendos

By Dow Jones

Próximas Ganancias

9 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

207M

Apertura anterior

4.28

Cierre anterior

4.03

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

180 / 386 Clasificación en Healthcare

Checkpoint Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 mar 2025, 10:23 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma

14 dic 2024, 00:24 UTC

Principales Movimientos del Mercado

Checkpoint Therapeutics' Shares Rise After Securing First FDA Approval

25 jul 2024, 13:02 UTC

Principales Movimientos del Mercado

Checkpoint Therapeutics Shares Rise After FDA Accepts Resubmission of Cosibelimab

10 mar 2025, 02:12 UTC

Adquisiciones, fusiones, absorciones

Checkpoint Controlling Shareholder Fortress Has Agreed to Vote in Favor of Transaction >524715.BY

10 mar 2025, 02:12 UTC

Adquisiciones, fusiones, absorciones

Sun Pharma, Checkpoint Transaction Expected to Complete in 2Q 2025 >524715.BY

10 mar 2025, 02:11 UTC

Adquisiciones, fusiones, absorciones

Sun Pharma, Checkpoint, Fortress Biotech Enter Into Royalty Agreement >524715.BY

10 mar 2025, 02:11 UTC

Adquisiciones, fusiones, absorciones

Checkpoint Shareholders Entitled to Receive Up to Additional $0.70 if Cosibelimab if Approved in EU Prior to Certain Deadlines >524715.BY

10 mar 2025, 02:10 UTC

Adquisiciones, fusiones, absorciones

Checkpoint Shareholders to Receive Upfront Cash Payment of $4.10/Share, Contingent Value Right >524715.BY

10 mar 2025, 02:10 UTC

Adquisiciones, fusiones, absorciones

Sun Pharma to Acquire Checkpoint Therapeutics >524715.BY CKPT

10 mar 2025, 02:06 UTC

Adquisiciones, fusiones, absorciones

Sun Pharma To Acquire Checkpoint Therapeutics >524715.BY CKPT

Comparación entre iguales

Cambio de precio

Checkpoint Therapeutics Inc previsión

Precio Objetivo

By TipRanks

31.19% repunte

Estimación a 12 Meses

Media 5.3 USD  31.19%

Máximo 7 USD

Mínimo 4.1 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Checkpoint Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

1

Comprar

2

Mantener

0

Vender

Sentimiento

By Acuity

180 / 386 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

$

Acerca de Checkpoint Therapeutics Inc

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with GC Cell. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.